Vanguard Personalized Indexing Management
ALLO icon

Vanguard Personalized Indexing Management’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Sell
67,811
-20,712
-23% -$45.5K ﹤0.01% 1994
2026
Q1 		$216K Buy
88,523
+20,735
+31% +$41.6K ﹤0.01% 1779
2025
Q4 		$92.9K Sell
67,788
-17,932
-21% -$23.7K ﹤0.01% 1814
2025
Q3 		$106K Buy
85,720
+14,032
+20% +$16.7K ﹤0.01% 1810
2025
Q2 		$81K Buy
71,688
+46,398
+183% +$61.7K ﹤0.01% 1765
2025
Q1 		$36.9K Buy
25,290
+4,777
+23% +$9.01K ﹤0.01% 1703
2024
Q4 		$43.7K Buy
20,513
+4,716
+30% +$11.6K ﹤0.01% 1708
2024
Q3 		$44.2K Buy
15,797
+5,398
+52% +$14.4K ﹤0.01% 1687
2024
Q2 		$24.2K Buy
+10,399
New +$30.7K ﹤0.01% 1635

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Personalized Indexing Management's ALLO Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Allogene Therapeutics (ALLO) stake by 23% in Q2 2026, selling an estimated $45.5K and leaving 67,811 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1994.

Vanguard Personalized Indexing Management first reported a position in ALLO in Q2 2024 and has held it in 9 quarters since. The position peaked at $216K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Vanguard Personalized Indexing Management held 67,811 shares of Allogene Therapeutics worth $141K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 20,712 Allogene Therapeutics shares in Q2 2026, an estimated $45.5K.
  • Allogene Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1994 holding.
  • Vanguard Personalized Indexing Management first reported a position in Allogene Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Vanguard Personalized Indexing Management's Allogene Therapeutics position peaked at $216K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.